Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 9/20 | 0.35 |
| ▸ | CA2 | P00918 | 9/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 2/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917760 | 0.98 | TSHR (0.39) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL8997124 | 0.98 | TSHR (0.39) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL4987261 | 0.93 | — | — | |
| SCHEMBL6798395 | 0.83 | — | — | |
| SCHEMBL27813414 | 0.76 | ADH1C (0.37) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL5490471 | 0.76 | CA1 (0.39) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL3139541 | 0.74 | ADH1C (0.36) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL1566319 | 0.74 | ADH1C (0.40) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL9767729 | 0.72 | ADH1C (0.39) | TSHRCA1CA2CA9LPAR3 | |
| SCHEMBL10771816 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103080080-A | 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments | BAYER IP GMBH | 2013-05-01 | — | — | CN | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TSHR 1903/4885CA1 4466/4885CA2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.